About trevena inc - TRVN
Trevena, Inc. is a biopharmaceutical company, which focuses on developing and commercializing novel medicines for patients affected by central nervous system, or CNS, disorders. Its product candidates include Oliceridine injection, TRV250, TRV734, and TRV045. The company was founded by Maxine Gowen, Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin, and Erin Whalen on November 9, 2007 and is headquartered in Atlanta, GA.
TRVN At a Glance
Trevena, Inc.
2870 Peachtree Road
Atlanta, Georgia 30305
| Phone | 1-610-354-8840 | Revenue | 3.13M | |
| Industry | Pharmaceuticals: Major | Net Income | -40,289,000.00 | |
| Sector | Health Technology | 2023 Sales Growth | 847.608% | |
| Fiscal Year-end | 12 / 2024 | Employees | 23 | |
| View SEC Filings |
TRVN Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 2.943 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.362 |
| Enterprise Value to Sales | 3.989 |
| Total Debt to Enterprise Value | 2.908 |
TRVN Efficiency
| Revenue/Employee | 135,869.565 |
| Income Per Employee | -1,751,695.652 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.07 |
TRVN Liquidity
| Current Ratio | 4.66 |
| Quick Ratio | 4.66 |
| Cash Ratio | 4.365 |
TRVN Profitability
| Gross Margin | 17.984 |
| Operating Margin | -1,129.216 |
| Pretax Margin | -1,279.072 |
| Net Margin | -1,289.248 |
| Return on Assets | -90.248 |
| Return on Equity | -1,014.581 |
| Return on Total Capital | -140.93 |
| Return on Invested Capital | -129.879 |
TRVN Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 126.784 |
| Total Debt to Total Assets | 89.262 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 123.244 |